NBIX Neurocrine Biosciences Inc
Price (delayed)
$103.06
Market cap
$10.28B
P/E Ratio
30.31
Dividend/share
N/A
EPS
$3.4
Enterprise value
$10.5B
Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological
Highlights
The price to earnings (P/E) is 70% lower than the 5-year quarterly average of 100.5 and 17% lower than the last 4 quarters average of 36.7
The gross profit has grown by 26% YoY and by 5% from the previous quarter
The company's net income rose by 37% YoY but it fell by 12% QoQ
Neurocrine Biosciences's quick ratio has increased by 36% YoY but it has decreased by 23% from the previous quarter
The debt has soared by 81% QoQ and by 6% YoY
Key stats
What are the main financial stats of NBIX
Market
Valuations
Earnings
Shares outstanding
99.7M
Market cap
$10.28B
Enterprise value
$10.5B
Price to earnings (P/E)
30.31
Price to book (P/B)
4.03
Price to sales (P/S)
4.39
EV/EBIT
21.6
EV/EBITDA
20.46
EV/Sales
4.46
Revenue
$2.36B
Gross profit
$2.32B
Operating income
$570.5M
Net income
$341.3M
EBIT
$486M
EBITDA
$513.1M
Free cash flow
$557.2M
Per share
Balance sheet
Liquidity
EPS
$3.4
EPS diluted
$3.29
Free cash flow per share
$5.55
Book value per share
$25.58
Revenue per share
$23.46
TBVPS
$36.68
Total assets
$3.72B
Total liabilities
$1.13B
Debt
$455.1M
Equity
$2.59B
Working capital
$1.22B
Debt to equity
0.18
Current ratio
3.4
Quick ratio
3.06
Net debt/EBITDA
0.43
Margins
Efficiency
Dividend
EBITDA margin
21.8%
Gross margin
98.6%
Net margin
14.5%
Operating margin
24.2%
Return on assets
9.7%
Return on equity
13.4%
Return on invested capital
15.9%
Return on capital employed
15.1%
Return on sales
20.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NBIX stock price
How has the Neurocrine Biosciences stock price performed over time
Intraday
-0.16%
1 week
1.66%
1 month
-10.85%
1 year
-25.84%
YTD
-24.5%
QTD
-6.82%
Financial performance
How have Neurocrine Biosciences's revenue and profit performed over time
Revenue
$2.36B
Gross profit
$2.32B
Operating income
$570.5M
Net income
$341.3M
Gross margin
98.6%
Net margin
14.5%
The operating income has surged by 127% year-on-year
The operating margin has soared by 82% YoY but it has contracted by 6% from the previous quarter
The company's net income rose by 37% YoY but it fell by 12% QoQ
The gross profit has grown by 26% YoY and by 5% from the previous quarter
Growth
What is Neurocrine Biosciences's growth rate over time
Valuation
What is Neurocrine Biosciences stock price valuation
P/E
30.31
P/B
4.03
P/S
4.39
EV/EBIT
21.6
EV/EBITDA
20.46
EV/Sales
4.46
The price to earnings (P/E) is 70% lower than the 5-year quarterly average of 100.5 and 17% lower than the last 4 quarters average of 36.7
NBIX's EPS is up by 33% year-on-year but it is down by 12% since the previous quarter
NBIX's price to book (P/B) is 41% lower than its 5-year quarterly average of 6.8 and 22% lower than its last 4 quarters average of 5.2
The company's equity rose by 16% YoY but it fell by 4.8% QoQ
The stock's price to sales (P/S) is 41% less than its 5-year quarterly average of 7.4 and 28% less than its last 4 quarters average of 6.1
Neurocrine Biosciences's revenue has increased by 25% YoY and by 5% QoQ
Efficiency
How efficient is Neurocrine Biosciences business performance
NBIX's return on sales is up by 17% year-on-year but it is down by 12% since the previous quarter
Neurocrine Biosciences's return on assets has decreased by 15% QoQ but it has increased by 8% YoY
The ROE has contracted by 15% from the previous quarter but it has grown by 3.9% YoY
The company's return on invested capital fell by 12% QoQ but it rose by 8% YoY
Dividends
What is NBIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NBIX.
Financial health
How did Neurocrine Biosciences financials performed over time
The company's current ratio rose by 39% YoY but it fell by 22% QoQ
The total liabilities has grown by 38% from the previous quarter and by 11% YoY
The debt is 82% lower than the equity
NBIX's debt to equity has surged by 100% since the previous quarter but it is down by 5% year-on-year
The debt has soared by 81% QoQ and by 6% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.